{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:58:16Z","timestamp":1790873896195,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":623,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.jacc.2011.08.051","type":"journal-article","created":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T04:42:54Z","timestamp":1321418574000},"page":"2263-2269","source":"Crossref","is-referenced-by-count":45,"title":["Safety and Efficacy of Antiplatelet and Antithrombotic Therapy in Acute Coronary Syndrome Patients With Chronic Kidney Disease"],"prefix":"10.1016","volume":"58","author":[{"given":"Sukhdeep S.","family":"Basra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser M.","family":"Lakkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jacc.2011.08.051_bib1","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. National Kidney Foundation","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2011.08.051_bib2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1161\/01.CIR.0000027560.41358.B3","article-title":"Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes","volume":"106","author":"Al Suwaidi","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.08.051_bib3","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0735-1097(02)02956-X","article-title":"Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb\/IIIa inhibitors","volume":"41","author":"Freeman","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2011.08.051_bib4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0735-1097(02)01745-X","article-title":"The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions","volume":"39","author":"Best","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2011.08.051_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"Wattanakit","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2011.08.051_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1055\/s-0038-1650576","article-title":"Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis","volume":"76","author":"Mezzano","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2011.08.051_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood.V68.2.337.337","article-title":"Defective platelet adhesion on vessel subendothelium in uremic patients","volume":"68","author":"Castillo","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2011.08.051_bib8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1053\/j.ackd.2008.07.006","article-title":"Risks and benefits of antiplatelet therapy in uremic patients","volume":"15","author":"Washam","year":"2008","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.jacc.2011.08.051_bib9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jacc.2007.02.028","volume":"50","author":"Anderson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2011.08.051_bib10","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/sj.ki.5001934","article-title":"The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease","volume":"70","author":"Charytan","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2011.08.051_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0735-1097(03)00572-2","article-title":"Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction","volume":"42","author":"Berger","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2011.08.051_bib12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1067\/mhj.2002.125513","article-title":"Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease","volume":"144","author":"McCullough","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2011.08.051_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1751-7141.2009.00050.x","article-title":"Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function","volume":"13","author":"Sciahbasi","year":"2010","journal-title":"Prev Cardiol"},{"key":"10.1016\/j.jacc.2011.08.051_bib14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.109.865352","volume":"121","author":"Fox","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.08.051_bib15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1525-139X.2006.00179.x","article-title":"Platelet dysfunction and end-stage renal disease","volume":"19","author":"Kaw","year":"2006","journal-title":"Semin Dial"},{"key":"10.1016\/j.jacc.2011.08.051_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","article-title":"First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease","volume":"45","author":"Baigent","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2011.08.051_bib17","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.ajkd.2007.07.007","article-title":"Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"50","author":"Ethier","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2011.08.051_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2011.08.051_bib19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2004.07.014","article-title":"ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction","volume":"44","author":"Antman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2011.08.051_bib20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","article-title":"The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"155","author":"Best","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2011.08.051_bib21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2011.08.051_bib22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.hjr.0000220582.19516.a6","article-title":"Renal function and outcomes in acute coronary syndrome: impact of clopidogrel","volume":"14","author":"Keltai","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.jacc.2011.08.051_bib23","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jacc.2009.10.043","article-title":"Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy","volume":"55","author":"Angiolillo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2011.08.051_bib24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00044011-199816040-00006","article-title":"Clopidogrel activities in patients with renal function impairment","volume":"16","author":"Deray","year":"1998","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jacc.2011.08.051_bib25","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.amjcard.2009.06.049","article-title":"A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure","volume":"104","author":"Park","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2011.08.051_bib26","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1016\/j.thromres.2010.08.009","article-title":"Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after acute coronary syndrome","volume":"126","author":"Cuisset","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2011.08.051_bib27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1527-3466.2007.00027.x","article-title":"Prasugrel: a novel thienopyridine antiplatelet agent","volume":"25","author":"Jakubowski","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.jacc.2011.08.051_bib28","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.08.051_bib29","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2011.08.051_bib30","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2710.2009.01068.x","article-title":"Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease","volume":"34","author":"Small","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jacc.2011.08.051_bib31","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2011.08.051_bib32","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2011.08.051_bib33","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2011.08.051_bib34","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.08.051_bib35","series-title":"Pharmacotherapy. A Pathophysiologic Approach","year":"2005"},{"key":"10.1016\/j.jacc.2011.08.051_bib36","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0002-9149(01)02267-6","article-title":"Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab","volume":"89","author":"Frilling","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2011.08.051_bib37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000127446","article-title":"Glycoprotein IIb\/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function","volume":"111","author":"Pinkau","year":"2008","journal-title":"Cardiology"},{"key":"10.1016\/j.jacc.2011.08.051_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.15420\/ahhj.2009.7.1.17","article-title":"In vitro inhibition of platelet aggregation in response to increasing concentrations of tirofiban in patients with significant renal insufficiency","volume":"7","author":"Alam","year":"2009","journal-title":"Am Heart Hosp J"},{"key":"10.1016\/j.jacc.2011.08.051_bib39","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction","volume":"338","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2011.08.051_bib40","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ahj.2004.12.002","article-title":"The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb\/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial","volume":"149","author":"Berger","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2011.08.051_bib41","series-title":"Integrellin (eptifibatide) [prescribing information]","year":"2005"},{"key":"10.1016\/j.jacc.2011.08.051_bib42","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Novel dosing regimen of Eptifibatide in Planned Coronary Stent Implantation (ESPRIT): a randomised, placebo-controlled trial","volume":"356","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2011.08.051_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0002-9149(02)02991-0","article-title":"Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT trial)","volume":"91","author":"Reddan","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2011.08.051_bib44","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1016\/j.jacc.2005.09.080","article-title":"Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial","volume":"47","author":"Kirtane","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2011.08.051_bib45","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1001\/jama.294.24.3108","article-title":"Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes","volume":"294","author":"Alexander","year":"2005","journal-title":"JAMA"},{"issue":"Suppl","key":"10.1016\/j.jacc.2011.08.051_bib46","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1378\/chest.108.4_Supplement.258S","article-title":"Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety","volume":"108","author":"Hirsh","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2011.08.051_bib47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1067\/mhj.2002.123112","article-title":"Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience","volume":"144","author":"Gilchrist","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2011.08.051_bib48","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina","volume":"276","author":"Oler","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2011.08.051_bib49","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","article-title":"Assessment of the treatment effect of enoxaparin for unstable angina\/non-Q-wave myocardial infarction","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.08.051_bib50","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis","volume":"355","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2011.08.051_bib51","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1067\/mhj.2002.126115","article-title":"Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin","volume":"144","author":"Cohen","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2011.08.051_bib52","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0002-8703(03)00165-0","article-title":"Combining enoxaparin and glycoprotein IIb\/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study","volume":"146","author":"Ferguson","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2011.08.051_bib53","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/01.CIR.0000050144.67910.13","article-title":"Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb\/IIIa inhibitor eptifibatide","volume":"107","author":"Goodman","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.08.051_bib54","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.08.051_bib55","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2011.08.051_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0049-3848(86)90039-3","article-title":"Low molecular weight heparin half life is prolonged in haemodialysed patients","volume":"43","author":"Goudable","year":"1986","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2011.08.051_bib57","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0049-3848(91)90141-I","article-title":"Delayed elimination of enoxaparin in patients with chronic renal insufficiency","volume":"63","author":"Cadroy","year":"1991","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2011.08.051_bib58","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1592\/phco.20.9.771.35210","article-title":"Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency","volume":"20","author":"Gerlach","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacc.2011.08.051_bib59","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.jacc.2006.12.049","article-title":"The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial","volume":"49","author":"Fox","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2011.08.051_bib60","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.beha.2004.03.004","article-title":"Fondaparinux: a new synthetic and selective inhibitor of Factor Xa","volume":"17","author":"Bauer","year":"2004","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jacc.2011.08.051_bib61","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2011.08.051_bib62","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7326\/0003-4819-147-5-200709040-00005","article-title":"Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes","volume":"147","author":"Fox","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2011.08.051_bib63","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2011.08.051_bib64","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2011.08.051_bib65","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jcin.2009.05.018","volume":"2","author":"Mehran","year":"2009","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2011.08.051_bib66","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2011.08.051_bib67","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.08.051_bib68","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2011.08.051_bib69","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jacc.2011.08.051_bib70","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.jacc.2007.02.065","article-title":"Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI 32 trial","volume":"49","author":"Giugliano","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2011.08.051_bib71","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.668434","article-title":"First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity","volume":"114","author":"Dyke","year":"2006","journal-title":"Circulation"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109711034218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109711034218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T08:41:06Z","timestamp":1596444066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109711034218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":71,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0735109711034218"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2011.08.051","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}